Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ana Martins da Silva is active.

Publication


Featured researches published by Ana Martins da Silva.


Neurology | 2005

Multiple Sclerosis Severity Score Using disability and disease duration to rate disease severity

R. H. S. R. Roxburgh; S Seaman; Thomas Masterman; Anke Hensiek; Stephen Sawcer; Sandra Vukusic; I. Achiti; Christian Confavreux; M. Coustans; E. le Page; G. Edan; Gavin McDonnell; Stanley Hawkins; Maria Trojano; Maria Liguori; Eleonora Cocco; M. G. Marrosu; F. Tesser; Marialucrez Leone; Alexandra Weber; Frauke Zipp; B. Miterski; Joerg T. Epplen; Annette Bang Oturai; P. S. Sørensen; Elisabeth G. Celius; N. T. Lara; Xavier Montalban; Pablo Villoslada; Ana Martins da Silva

Background: There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease. Methods: Using data from two large longitudinal databases, the authors tested whether cross-sectional disability assessments are representative of disease severity as a whole. An algorithm, the Multiple Sclerosis Severity Score (MSSS), which relates scores on the Expanded Disability Status Scale (EDSS) to the distribution of disability in patients with comparable disease durations, was devised and then applied to a collection of 9,892 patients from 11 countries to create the Global MSSS. In order to compare different methods of detecting such effects the authors simulated the effects of a genetic factor on disability. Results: Cross-sectional EDSS measurements made after the first year were representative of overall disease severity. The MSSS was more powerful than the other methods the authors tested for detecting different rates of disease progression. Conclusion: The Multiple Sclerosis Severity Score (MSSS) is a powerful method for comparing disease progression using single assessment data. The Global MSSS can be used as a reference table for future disability comparisons. While useful for comparing groups of patients, disease fluctuation precludes its use as a predictor of future disability in an individual.


Clinical & Developmental Immunology | 2015

The Protective Role of HLA-DRB1∗13 in Autoimmune Diseases

Andreia Bettencourt; Cláudia Carvalho; Bárbara Leal; Sandra Brás; Dina Lopes; Ana Martins da Silva; Ernestina Santos; Tiago Torres; Isabel Almeida; Fátima Farinha; P. F. Barbosa; António Marinho; Manuela Selores; João Araújo Correia; Carlos Vasconcelos; Paulo Costa; Berta Martins da Silva

Autoimmune diseases (AIDs) are characterized by a multifactorial aetiology and a complex genetic background, with the MHC region playing a major role. We genotyped for HLA-DRB1 locus 1228 patients with AIDs-213 with Systemic Lupus Erythematosus (SLE), 166 with Psoriasis or Psoriatic Arthritis (Ps + PsA), 153 with Rheumatoid Arthritis (RA), 67 with Systemic Sclerosis (SSc), 536 with Multiple Sclerosis (MS), and 93 with Myasthenia Gravis (MG) and 282 unrelated controls. We confirmed previously established associations of HLA-DRB1∗15 (OR = 2.17) and HLA-DRB1∗03 (OR = 1.81) alleles with MS, HLA-DRB1∗03 with SLE (OR = 2.49), HLA-DRB1∗01 (OR = 1.79) and HLA-DRB1∗04 (OR = 2.81) with RA, HLA-DRB1∗07 with Ps + PsA (OR = 1.79), HLA-DRB1∗01 (OR = 2.28) and HLA-DRB1∗08 (OR = 3.01) with SSc, and HLA-DRB1∗03 with MG (OR = 2.98). We further observed a consistent negative association of HLA-DRB1∗13 allele with SLE, Ps + PsA, RA, and SSc (18.3%, 19.3%, 16.3%, and 11.9%, resp., versus 29.8% in controls). HLA-DRB1∗13 frequency in the AIDs group was 20.0% (OR = 0.58). Although different alleles were associated with particular AIDs, the same allele, HLA-DRB1∗13, was underrepresented in all of the six diseases analysed. This observation suggests that this allele may confer protection for AIDs, particularly for systemic and rheumatic disease. The protective effect of HLA-DRB1∗13 could be explained by a more proficient antigen presentation by these molecules, favouring efficient clonal deletion during thymic selection.


Multiple Sclerosis Journal | 2015

Cognitive reserve in multiple sclerosis: Protective effects of education.

Ana Martins da Silva; Sara Cavaco; Inês Moreira; Andreia Bettencourt; Ernestina Santos; Cláudia Pinto; Alexandra Gonçalves; Ester Coutinho; Raquel Samões; Cláudia Dias; Armando Teixeira-Pinto; Berta Martins da Silva; Xavier Montalban

Background: Recent data suggest that cognitive reserve modulates the adverse effects of multiple sclerosis (MS) pathology on cognitive functioning; however, the protective effects of education in MS are still unclear. Objective: To explore education as an indicator of cognitive reserve, while controlling for demographic, clinical and genetic features. Methods: A total of 419 MS patients and 159 healthy comparison (HC) subjects underwent a comprehensive neuropsychological (NP) assessment, and answered the Hospital Anxiety and Depression Scale. Based on the HC data, MS patients’ NP scores were adjusted for sex, age and education; and the estimated 5th percentile (or 95th percentile, when appropriate) was used to identify any deficits. Patients also performed the Mini-Mental State Examination (MMSE); and their human leucocyte antigen HLA-DRB1 and apolipoprotein E (ApoE) genotypes were investigated. Results: Patients with higher education were less likely (p < 0.05) to have cognitive deficits than those with lower education, even when controlling for other covariates. Other significant predictors of cognitive deficit were: age, Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), and a progressive course. No significant association was found with the HLA-DRB1*15:01 or ApoE ε4 alleles. Conclusions: These results provide support to the use of education as a proxy of cognitive reserve in MS and stress the need to take into account education when approaching cognition in MS.


Multiple Sclerosis Journal | 2012

Olfactory dysfunction in multiple sclerosis: association with secondary progression

Ana Martins da Silva; Ernestina Santos; Inês Moreira; Andreia Bettencourt; Ester Coutinho; Alexandra Gonçalves; Cláudia Pinto; Xavier Montalban; Sara Cavaco

Objective: The Brief Smell Identification Test (B-SIT) was used to explore odour identification capacities in multiple sclerosis (MS). Methods: In total, 153 consecutive patients with MS and 165 healthy controls (HC) participated in the study. All participants were asked to answer the B-SIT and the Hospital Anxiety and Depression Scale (HADS). The Expanded Disability Status Scale (EDSS), the Multiple Sclerosis Severity Scale (MSSS), and the Mini-Mental State Examination (MMSE) were used for patients’ clinical and cognitive characterization. Results: Patients with MS (11.1%) were more impaired on the B-SIT than HC participants (3%). The frequency of impairment was higher for patients with secondary progressive (SPMS; 11/16, 68.8%) than relapsing–remitting (RRMS; 4/121, 3.3%) or primary progressive (2/16, 12.5%) courses. A threshold score of ≤ 8 on the B-SIT provided a sensitivity of 69% and a specificity of 97% in the identification of SPMS among patients with relapsing onset. The association between SPMS and impaired B-SIT remained statistically significant after adjusting for demographic (i.e. age and education), clinical (i.e. disease duration, EDSS, and MSSS), psychopathological (i.e. HADS anxiety and depression scores), and cognitive (i.e. MMSE) variables. Conclusions: A brief odour identification measure provided a good discrimination between SPMS and RRMS courses. A systematic assessment of olfactory functions may contribute to the development of clinical markers of SPMS.


Annals of the New York Academy of Sciences | 2009

Cognitive Functioning in Behcet's Disease

Sara Cavaco; Ana Martins da Silva; Pedro S. Pinto; Ester Coutinho; Ernestina Santos; Andreia Bettencourt; Cláudia Pinto; Alexandra Gonçalves; Susana Silva; Filomena Gomes; Luísa Carvalho; Cláudia V. Pereira; Berta Martins; João Araújo Correia; Carlos Vasconcelos

The impact of Behçets disease on higher cognitive functions is still poorly understood. We proposed (1) to characterize the neuropsychological profile of Behçets disease patients with (Neuro‐BD) and without (BD) neurological manifestations; (2) to identify which clinical, psychopathological, and genetic variables are related to neuropsychological performance; and (3) to explore the association between cognitive functioning and neuroimaging findings in BD patients. Fifteen Neuro‐BD and 35 BD patients in the nonactive phase of their illness underwent a neurological examination, performed a comprehensive battery of neuropsychological tests, and answered the hospital anxiety and depression scale. Human leukocyte antigen (HLA)‐B*51 genotyping was also performed. Patients’ neuropsychological performances were compared to those of healthy demographically matched subjects. Within one month from the testing date, a subset of 20‐BD patients underwent a magnetic resonance imaging (MRI) scan. Fifty‐three percent of Neuro‐BD and 40% of BD patients were impaired at least on one neuropsychological measure (i.e., digit span–forward). Poorer cognitive functioning in Neuro‐BD was associated with parenchymal involvement, whereas in BD it was related to presence of white matter changes in the frontal lobes, history of headache complaints, or higher levels of anxiety and depression. Current prednisone intake had a positive impact on neuropsychological performance. Disease duration, time since onset of neurological manifestations, or presence of HLA‐B*51 allele had no significant influence. Our results indicate that Behçets disease may affect cognitive abilities in the absence of overt neurological symptoms. These findings point to an insidious course of neurological involvement.


Clinical Reviews in Allergy & Immunology | 2012

Systemic Lupus Erythematosus, Progressive Multifocal Leukoencephalopathy, and T-CD4+ Lymphopenia

Mariana Brandão; Joana Damásio; António Marinho; Ana Martins da Silva; Júlia Vasconcelos; Esmeralda Neves; Isabel Almeida; Fátima Farinha; Carlos Vasconcelos

Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection caused by the reactivation of JC virus and occurs in patients with severe primary or secondary immunosuppression. Recently, PML is becoming relevant in autoimmune disorders, particularly in patients treated with biologic agents. However, systemic lupus erythematosus (SLE) appears to be associated with susceptibility to PML that cannot be entirely explained by the immunosuppressive therapy. The authors present two patients with the diagnosis of SLE and PML: One had a heavy immunosuppressive therapy history, and the other had never experienced biologic or cytotoxic therapeutics. Both patients had a profound T-CD4+ lymphopenia during their clinical history. These two cases emphasize the importance of CD4+ lymphopenia in SLE patients with and without immunosuppressors regarding opportunistic infections.


Tissue Antigens | 2008

New insights of HLA class I association to Behçet’s disease in Portuguese patients

Andreia Bettencourt; Clara Pereira; L. Carvalho; C. Carvalho; J. V. Patto; M. Bastos; Ana Martins da Silva; R. Barros; Carlos Vasconcelos; P. Paiva; L. Costa; Paulo Costa; Denisa Mendonça; João Araújo Correia; B. M. Silva

Human leukocyte antigen (HLA)-B*51 is a well-known genetic factor associated with Behçets disease (BD). To analyse the influence of HLA-B*51 and other HLA class I alleles in BD susceptibility in a Portuguese population and its association with disease severity, we studied 78 BD patients and 208 healthy controls. The patients were classified into two severity groups as described by Gul et al. As expected, a higher frequency of HLA-B*51 was found. The frequency of HLA-Cw*16 alleles was significantly higher in patients. Regarding severity, HLA-B*27 frequency was higher in the severe group compared with controls and with the mild group. Thus, HLA-B*51 and HLA-Cw*16 seem to confer susceptibility to BD in this patients. HLA-B*27 may be important as a prognostic factor.


The Journal of Rheumatology | 2012

Are Cognitive and Olfactory Dysfunctions in Neuropsychiatric Lupus Erythematosus Dependent on Anxiety or Depression

Sara Cavaco; Ana Martins da Silva; Ernestina Santos; Ester Coutinho; António Marinho; Inês Moreira; Alexandra Gonçalves; Cláudia Pinto; Armando Teixeira-Pinto; Carlos Vasconcelos

Objective. Depressed mood and cognitive impairments are common findings in systemic lupus erythematosus (SLE) and frequently coexist. We assessed the neuropsychological functioning of patients with SLE and investigated its association with psychopathological symptoms. Methods. A total of 85 patients with SLE (28 with neuropsychiatric syndromes: NPSLE) and 85 healthy control subjects with similar demographic characteristics were asked to perform a series of neuropsychological tests. A self-report questionnaire (the Hospital Anxiety and Depression Scale) was used to screen for psychopathology symptoms. Patients with SLE underwent a neurological examination. Results. Patients with NPSLE were more depressed and were more frequently impaired in cognitive and olfactory functions than controls or non-NPSLE patients. The NPSLE group remained statistically different from the other 2 groups on a series of neuropsychological measures (the Auditory Verbal Learning Test, Trail Making Test – Part A, Nine-Hole Peg Test, and Brief Smell Identification Test) even after control for elevated anxiety and depressed mood. Non-NPSLE and control groups were not significantly different regarding either psychopathological symptoms or neuropsychological functioning. Conclusion. Verbal memory, psychomotor speed, and olfaction are particularly vulnerable to dysfunction in NPSLE; impairment in these neuropsychological domains is not completely explained by psychopathology symptoms.


Journal of Neuroimmunology | 2014

The role of KIR2DS1 in multiple sclerosis - KIR in Portuguese MS patients

Andreia Bettencourt; Ana Martins da Silva; Cláudia Carvalho; Bárbara Leal; Ernestina Santos; Paulo Costa; Berta Martins da Silva

Killer Immunoglobulin-like Receptor (KIR) genes may influence both resistance and susceptibility to different autoimmune diseases, but their role in the pathogenesis of Multiple Sclerosis (MS) is still unclear. We investigated the influence of KIR genes on MS susceptibility in 447 MS Portuguese patients, and also whether genetic interactions between specific KIR genes and their HLA class I ligands could contribute to the pathogenesis of MS. We observed a negative association between the activating KIR2DS1 gene and MS (adjusted OR=0.450, p=0.030) independently from the presence of HLA-DRB1*15 allele. The activating KIR2DS1 receptor seems to confer protection against MS most probably through modulation of autoreactive T cells by Natural Killer cells.


European Journal of Neurology | 2011

HFE gene polymorphisms and severity in Portuguese patients with multiple sclerosis

Andreia Bettencourt; Ana Martins da Silva; Ernestina Santos; Susana Gomes; Denisa Mendonça; Paulo Costa; Paula Faustino; Berta Martins da Silva

Background:  High iron concentrations have been reported in oligodendrocytes, myelin and macrophages in multiple sclerosis (MS) lesions. It has been proposed that HFE gene polymorphisms could have a role in MS.

Collaboration


Dive into the Ana Martins da Silva's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge